pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX
CATALYST PHARMACEUTICALS
CATALYST PHARMACEUTICALS, INC.
Catalyst Pharmaceuticals is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker CPRX. Primary therapeutic focus areas include Hemophilia A With Inhibitor, Hemophilia A, Hemophilia B,
355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US HQ
2002 Founded
179 Employees
Public company Type
CPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
- Founded
- 2002
- Employees
- 179
- Programs
- 23
- Drugs
- 20
- Patents
- 61
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Phase 1 · mab · Hemophilia B
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg for Hemophilia B is a Phase 1 program (mab) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Internal code ISU304-001/CB2679d
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CATALYST PHARMACEUTICALS, INC.
- Phase
- Phase 1
- Modality
- mab
- Indication
- Hemophilia B
- Status
- completed
- Trials
- 1